GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Median Diagnostics Inc (XKRX:233250) » Definitions » EBIT

Median Diagnostics (XKRX:233250) EBIT : ₩-1,235 Mil (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Median Diagnostics EBIT?

Median Diagnostics's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was ₩-1,235 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-1,235 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Median Diagnostics's annualized ROC % for the quarter that ended in Dec. 2023 was -10.17%. Median Diagnostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -10.58%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Median Diagnostics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -6.52%.


Median Diagnostics EBIT Historical Data

The historical data trend for Median Diagnostics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Median Diagnostics EBIT Chart

Median Diagnostics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only 668.55 2,256.56 2,645.75 323.36 -1,234.70

Median Diagnostics Semi-Annual Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only 668.55 2,256.56 2,645.75 323.36 -1,234.70

Competitive Comparison of Median Diagnostics's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Median Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Median Diagnostics's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Median Diagnostics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Median Diagnostics's EV-to-EBIT falls into.



Median Diagnostics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-1,235 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Median Diagnostics  (XKRX:233250) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Median Diagnostics's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-1250.642 * ( 1 - -8.05% )/( (14401.738 + 12181.84)/ 2 )
=-1351.318681/13291.789
=-10.17 %

where

Invested Capital(Q: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=24333.313 - 2112.79 - ( 7818.785 - max(0, 3685.008 - 16535.802+7818.785))
=14401.738

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=21723.872 - 792.012 - ( 8750.02 - max(0, 2419.423 - 13698.446+8750.02))
=12181.84

Note: The Operating Income data used here is one times the annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Median Diagnostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2022  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1234.702/( ( (6791.859 + max(5989.968, 0)) + (7169.755 + max(3381.58, 0)) )/ 2 )
=-1234.702/( ( 12781.827 + 10551.335 )/ 2 )
=-1234.702/11666.581
=-10.58 %

where Working Capital is:

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3947.918 + 4348.453 + 240.77) - (2112.79 + 0 + 434.383)
=5989.968

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1431.976 + 2852.199 + 380.897) - (792.012 + 0 + 491.48)
=3381.58

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Median Diagnostics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-1234.702/18924.388
=-6.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Median Diagnostics EBIT Related Terms

Thank you for viewing the detailed overview of Median Diagnostics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Median Diagnostics Business Description

Traded in Other Exchanges
N/A
Address
878 Seoul Office, Dongnae-dong, Kangwon-do, Chuncheon, KOR, 200-883
Median Diagnostics Inc is a Korea based company engaged in providing IVD solutions and veterinary diagnostics services. Its solutions portfolio covers avian influenza diagnosis solution, foot and mouth disease diagnosis solution, African Pig fever solution and others. The company offers ELISA diagnostic products, rapid test kit, molecular diagnosis products, standard diagnosis products and biologicals.

Median Diagnostics Headlines

No Headlines